NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

While OS is better in rGBM the long tail from early treatment stomps the long tail of rGBM convincingly hence the likely reason for the hold. Best wishes

That data has not been published and you cannot extract it from the NYAS data.

One can try to use the 2018 LL SNO data to work the numbers on the N=99 arm even though not mature. That comes out with those having a fatter tail though.

Besides that, you have the problem that there was little long erm data back then. The 17 enrolled in 2007'-8 would have produced a couple. Since then no patient was on trial over 4 years.